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Abstract
An increased interest in gastro-entero-pancreatic neuroendocrine neoplasms (GEP NENs) has recently been observed. These are rare neo-
plasms and their detection in recent years has improved. Over 50% of GEP NENs are carcinoids, and they are usually found incidentally 
during surgery in the small intestine and appendix and at diagnosis in distant metastases, mainly to the liver.
There is a need for co-operation between specialists in various disciplines of medicine in order to work out the diagnostic and therapeutic guidelines.
In this publication, we present general recommendations of the Polish Network of Neuroendocrine Tumours for the management of 
patients with GEP NENs, developed at the Consensus Conference which took place in Kamień Śląski in April 2013. Members of the 
guidelines working groups were assigned sections of the 2008 guidance to update. 
In the subsequent parts of this publication, we present the rules of diagnostic and therapeutic management of:
— neuroendocrine neoplasms of the stomach and duodenum (including gastrinoma);
— pancreatic neuroendocrine neoplasms;
— neuroendocrine neoplasms of the small intestine and the appendix;
— colorectal neuroendocrine neoplasms.
The proposed recommendations by Polish and foreign experts representing different fields of medicine (endocrinology, gastroen-
terology, surgery, oncology, nuclear medicine and pathology) will be helpful in the diagnosis and treatment of GEP NENs patients. 
(Endokrynol Pol 2013; 64 (6): 418–443)
Key words: gastro-entero-pancreatic neuroendocrine neoplasm; diagnosis; therapy
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1. Epidemiology
Gastro-entero-pancreatic neuroendocrine neoplasms 
(GEP NENs) arise from the diffuse endocrine system 
(DES) cells disseminated in the gastrointestinal tract 
and in the pancreas [1]. The detection rate for neuroen-
docrine neoplasms (NENs) has risen in recent years. 
Between 1973 and 2004, NEN incidence increased from 
2.1 to 5.25 new cases/100,000 persons/year, with the 
most commonly described primary site being the small 
intestine (37.4%). According to epidemiological studies 
conducted in the USA (SEER, the Surveillance Epidemi-
ology End Results) and Norway (NRC, the Norwegian 
Registry of Cancer), an increase in the incidence of gastric 
and rectal NENs has been observed, as well as a lower 
incidence of NENs of the appendix [1, 2]. According 
to the SEER data, these tumours are most frequently 
diagnosed in African-Americans, the incidence rate be-
ing 6.5/100,000/year [2], and the most common primary 
tumour site is in the rectum (27%). Among those of 
Caucasian race, the lung is the most common primary 
tumour site (30% of new cases of NENs) [3]. Presently, 
the mean general prevalence rate for these neoplasms 
is 35 cases in 100,000. A slight predominance of male pa-
tients (5.35/100,000/year) has been observed, compared 
to females (4.76/100,000/year) [2, 4]. No predisposing 
factors for NENs have been described, although in-
creases in the diagnoses of NEN have been observed in 
patients with atrophic gastritis, and in Afro-Caribbean 
patients [5]. Approximately 70% of neuroendocrine 
neoplasms are GEP NENs, which account for ca. 2% 
of all gastrointestinal neoplasms [6, 7]. They constitute 
a rare, heterogeneous group of neoplasms [8, 9]. The 
molecular basis for the development of NENs is still 
unclear, but new reports indicate that identification 
of common genetic factors might be useful in creating 
a new classification system, and they could become new 
Streszczenie
W ostatnim czasie obserwuje się większe zainteresowanie rzadkimi nowotworami neuroendokrynnymi żołądkowo-jelitowo-trzustkowymi 
(GEP NEN). Wykrywalność nowotworów neuroendokrynnych w ostatnich latach wzrosła. Ponad 50% GEP NEN stanowią rakowiaki, które 
najczęściej są znajdowane przypadkowo podczas zabiegu operacyjnego w jelicie cienkim i w wyrostku robaczkowym oraz w momencie 
rozpoznania przerzutów odległych, głównie do wątroby. Istnieje konieczność współdziałania specjalistów różnych dziedzin medycyny 
w celu opracowania właściwych zasad postępowania diagnostyczno-leczniczego w tej grupie chorych. 
W niniejszej publikacji przedstawiono ogólne zalecenia Polskiej Sieci Guzów Neuroendokrynnych dotyczące postępowania u chorych 
z GEP NEN, opracowane podczas Konferencji, która odbyła się w Kamieniu Śląskim w kwietniu w 2013 roku. Członkowie grup roboczych 
zaktualizowali rekomendacje z 2008 roku.
W kolejnych częściach tego opracowania przedstawiono zasady postępowania w:
— nowotworach neuroendokrynnych żołądka i dwunastnicy (z uwzględnieniem gastrinoma);
— nowotworach neuroendokrynnych trzustki;
— nowotworach neuroendokrynnych jelita cienkiego i wyrostka robaczkowego;
— nowotworach neuroendokrynnych jelita grubego.
Zaproponowane rekomendacje przez ekspertów polskich i zagranicznych reprezentujących różne dziedziny medycyny (endokrynologię, 
gastroenterologię, chirurgię, onkologię, medycynę nuklearną i patomorfologię) powinny być pomocne w diagnostyce i leczeniu tych 
chorych. (Endokrynol Pol 2013; 64 (6): 418–443)
Słowa kluczowe: nowotwory neuroendokrynne żołądkowo-jelitowo-trzustkowe; diagnostyka; leczenie
elements affecting tumour progression [9–11]. These 
neoplasms may demonstrate hormonal activity, and 
then they are referred to as functional tumours. Some of 
them do not produce hormones and/or biogenic amines 
in quantities sufficient to present clinical symptoms, so 
they are called non-functional tumours. Over 50% of 
GEP NENs are carcinoids, and they are most frequently 
found accidentally, during a surgical procedure, in the 
small intestine and in the appendix, as well as at the 
diagnosis of distant metastases, mostly to the liver [12]. 
The incidence rate of NENs, both functional and 
non-functional, derived from different parts of the 
gastrointestinal tract and the pancreas, is discussed in 
other sections of this document.
2. Diagnostics
2.1. Biochemical diagnostics
In biochemical diagnostics of NENs, the following 
should be considered:
A. Non-specific markers
Determination of serum chromogranin A (CgA) con-
centration is the most commonly used test [13–15]. CgA 
is a secretory acidic protein produced in the granules 
of diffuse endocrine system cells. Therefore, immuno-
histochemical assessment of CgA and synaptophysin 
expression in the histopathological material is essential 
for the diagnosis of NEN. In blood, CgA is a relatively 
stable protein. However, there are different methods 
of determination of CgA concentration: radioimmu-
nological (RIA) or enzymatic (ELISA) methods using 
blood serum or plasma [16]. Unfortunately, there are 
no international CgA standards, and the differences 
between available tests are significant. To monitor the 
course of the disease, it is recommended to determine 
CgA concentration using the same method [11, 12]. 
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Chromogranin A assay is useful in:
1. Diagnosing NEN. CgA values are often increased 
in most GEP NENs, particularly in advanced disease, 
but results within the reference range do not exclude 
the diagnosis of NEN. CgA concentration depends on 
a few factors (Fig. 1). 
The sensitivity of the CgA concentration test varies 
in different neoplasms, ranging from 10% to 100%, and 
its specificity is 68–100%. The highest sensitivity has 
been observed in gastrinoma, glucagonoma and small 
intestinal NENs. Particularly high CgA concentrations 
are found in NENs of the small intestine, with hepatic 
metastases and carcinoid syndrome, where the CgA 
concentration may be increased by as much as a few 
dozen times. On the other hand, in benign insulinoma, 
CgA concentrations are often within the reference 
range. In neuroendocrine carcinomas (NEC), CgA con-
centrations are often lower than in well-differentiated 
tumours (G1, G2 NEN). A concentration exceeding the 
reference values is not always caused by NEN, and it is 
not tantamount to a diagnosis [17–20]. Therefore, while 
interpreting the CgA results, it is necessary to know the 
test that has been used and possible causes for false 
positives or false negatives (Table I) [11,12].
2. As a prognostic factor for survival and a marker 
for monitoring the course of the disease and GEP 
NEN treatment. CgA concentrations are independent 
prognostic factors for survival in patients with small 
intestinal and pancreatic NENs [21]. Using somatostatin 
analogues (SSA) considerably lowers CgA concentra-
tions; in cases of progressing disease, increased CgA 
concentration during treatment with SSA may reflect 
a lack of control of tumour secretory function and/or 
its growth. An early decrease of CgA concentration in 
patients with pancreatic NEN during treatment with 
everolimus is also a favourable prognostic factor for 
progression-free survival [21].
Another non-specific NEN marker is neuron-specific 
enolase (NSE). Generally, NSE is characterised by lower 
sensitivity and specificity (30-50%) in diagnosing GEP 
NEN, compared to CgA [13]. Increased NSE concentra-
tion may be associated with poorly differentiated NEC. 
Therefore, simultaneous CgA and NSE determination 
is more sensitive and specific in the diagnosis of NEN. 
NSE is also a prognostic factor for survival and a marker 
for monitoring the treatment of pancreatic NENs [21]. 
Pancreatic polypeptide (PP) may be a useful marker 
of non-functional pancreatic NENs, especially those as-
sociated with MEN1 (sensitivity 50–80% in pancreatic 
NENs and > 30% in all NENs). 
In the differential diagnostics of increased PP con-
centration, one should consider not only diarrhoea, 
laxatives, intestinal inflammation and chronic renal 
diseases, but also ingested meal, physical effort and 
advanced age [13]. The availability of the test in Poland 
is limited.
Due to high availability, β-subunit of human cho-
rionic gonadotropin (HCG) is often determined in 
patients with NENs, but the test value is limited and 
not clearly established, compared to CgA. 
Chromogranin B (CgB) is also mentioned as a non-
specific marker, as its concentration may be increased 
in insulinoma, rectal NENs and NENs of the ovaries. 
Pancreostatin is part of CgA, and studies have suggested 
that PPI does not affect pancreostatin concentration. The 
availability of these tests in Poland is also limited [13].
B. Specific markers
The choice of specific GEP NEN markers depends 
on the clinical manifestation and type of neoplasm 
suspected (Table II) [8, 18, 22, 23]. Direct measurement 
Figure 1. Neoplastic factors affecting CgA concentration 
Rycina 1. Czynniki nowotworowe wpływające na stężenie CgA
Table I. Reasons for increased serum CgA concentration other 
than GEP NEN [11, 12]
Tabela I. Inne niż GEP NEN przyczyny podwyższonego 
stężenia CgA w surowicy [11, 12]
Reasons for increased serum CgA concentration other than GEP 
NEN:
receiving proton pump inhibitors and histamine H2-receptor blockers 
(if possible, they should be discontinued at least 7–14 days before 
the test)
atrophic gastritis
renal failure
meal or physical effort 2-4 hours before the blood draw
other neoplasms: prostate cancer, small cell lung carcinoma, medullary 
thyroid cancer, pheochromocytoma, hepatic cancer, pancreatic 
adenocarcinoma
Other non-neoplastic causes of increased CgA concentration (usually 
with a lesser effect on CgA levels):
chronic inflammations, including rheumatoid arthritis (presence of IgM 
rheumatoid factor), COPD
gastrointestinal diseases, including inflammatory bowel disease, 
hepatitis, cirrhosis, and pancreatitis
cardio-vascular diseases, including cardiac failure, cardiac infarction
endocrine diseases, including hyperthyroidism or hyperparathyroidism, 
treatment with glucocorticoids
other, e.g. Parkinson’s disease
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of concentrations of specific peptides, biogenic amines 
and hormones produced by NEN cells is useful not only 
in diagnosing, but also in monitoring the treatment of, 
GEP NENs [18]. 
This article will discuss laboratory diagnostics in 
carcinoid syndrome. Details of biochemical diagnostics 
in other clinical syndromes are discussed in other sec-
tions of our recommendations. 
The most frequently observed set of clinical symp-
toms associated with hormonal activity of NEN is 
carcinoid syndrome. The clinical picture is discussed 
in the section on NEN of the small intestine and the 
appendix. The classical form mainly depends on exces-
sive serotonin secretion. The atypical form is observed 
in pulmonary carcinoid tumours and gastric NENs; 
it depends on excessive secretion of serotonin, 5-hy-
droxytryptophan (5-HT; serotonin precursor) and/or 
histamine. 
Serotonin is produced by 70% of NENs, mostly 
arising in the small intestine, including the ileum, the 
proximal large intestine, the appendix and in 10–35% 
of gastric and pulmonary NENs. The screening test 
for carcinoid syndrome includes two assays of daily 
urinary excretion of a serotonin metabolite: 5-hydrox-
yindoleacetic acid (5-HIAA), provided a proper diet has 
been followed. It is also important to acidify the urine 
during the sample collection (Table III). The reference 
range is 2-8 mg/day (10–42 mmol/d). Possible false-
positives and false-negatives are presented in Table III 
[13, 17, 18].
In unclear cases, serum serotonin concentration 
may be determined. During the measurement of blood 
serotonin concentration, it is important to remember 
frequent pre-laboratory errors due to the considerable 
serotonin storage in blood platelets. Determination of 
blood 5-HT or histamine is limited [13, 17, 18].
C. Ectopic hormone production and single-gene 
inherited multi-gland syndromes 
It is also noteworthy that gastrointestinal NENs 
(mostly of the pancreas) may cause ectopic produc-
tion of ACTH (causing ACTH-dependent Cushing’s 
syndrome), GHRH (causing acromegaly), vasopressin 
(causing SIADH), and PTH-RP (causing hypercalcemia). 
Diagnostics of these syndromes depends on the 
clinical symptoms [12].
In all patients with foregut NENs, particularly pa-
tients with NENs of the thymus, duodenum (gastrino-
ma) and pancreas, examinations for multiple endocrine 
neoplasia type 1 (MEN1) should be performed [20, 21]. 
Basic screening tests in MEN1 include concentrations of 
ionised or total calcium, parathyroid hormone (intact 
PTH), gastrin, prolactin and growth hormone (GH) or 
IGF-1. In patients with suspected MEN1, molecular tests 
should be considered to detect mutation in the MEN1 
menin-coding gene. 
Moreover, pancreatic NEN may occur in von Hippel-
Lindau syndrome, and very rare duodenal NENs, 
somatostatinomas, may occur in patients with type 1 
neurofibromatosis [12, 20].
Minimal consensus statement on biochemical diagnostics:
 — in patients with suspected NEN, CgA concentration 
should be determined (*evidence level 3);
 — in patients diagnosed with NEN, CgA concentration 
should be determined (*evidence level 3) — also concen-
tration of hormones and substances specific for a given 
syndrome, depending on the clinical symptoms presented 
by the patient;
 — if MEN1 is suspected, it is recommended to determine 
the concentration of ionised calcium, parathyroid hor-
mone (PTH), pituitary hormones (prolactin, GH), and 
to consider conducting genetic tests (*evidence level 3).
* evidence level according to CEBM [145]
Table II. Selected biochemical markers in the diagnostics of GEP NENs [8, 18, 24, 25]
Tabela II. Wybrane markery biochemiczne w diagnostyce GEP NEN [8, 18, 24, 25]
Primary NEN Clinical picture Biochemical markers
Stomach, type I, II Atrophic gastritis Gastrin
Duodenum, stomach type II Zollinger-Ellison syndrome Gastrin
Duodenum, pancreas Somatostatinoma SST (somatostatin)
Small intestine, ileum, proximal large intestine Classical carcinoid syndrome 5HIAA
Pancreas Insulinoma glucose, insulin, peptide C
Zollinger-Ellison syndrome Gastrin
Glucagonoma Glucagon
Verner-Morrison syndrome VIP
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2.2. Pathomorphological diagnostics
2.2.1. The WHO 2010 classification of GEP NENs 
Further changes in the pathomorphological diagnostics 
of GEP NENs were introduced in 2010, when NENs 
were divided into two basic groups: either well-differ-
entiated or poorly-differentiated neoplasms. 
This was proposed by the WHO and adopted. 
It was primarily based on an assessment of tumour 
morphology compared to the structures created by 
non-neoplastic cells. Another parameter was tumour 
grading (G), which reflected the potential clinical be-
haviour of the neoplasm. Compared to the classification 
system of 2000, the major difference was in referring to 
well-differentiated tumours and well-differentiated car-
cinomas by the same term — neuroendocrine tumours/ 
/neoplasms (NEN), while the G feature determined 
their grade (G1 or G2). Secondly, poorly-differentiated 
neuroendocrine small cell or large cell type (G3) cancers 
were referred to as neuroendocrine carcinomas (NEC), 
and treated as classical cancers with regard to their di-
agnostic criteria and treatment methods [26–28]. Tables 
IV and V present the WHO NENs classification systems 
introduced in 1980, 2000 and 2010.
The histopathological grade (G) appears to be the 
key microscopic feature with a prognostic and a predic-
tive value in the treatment of patients with gastrointes-
tinal NENs. As mentioned before, it is an independent 
parameter dividing NENs into three groups, accord-
ing to the predicted clinical behaviour of the disease: 
lesions of low (G1), intermediate (G2) and high (G3) 
malignancy. The criteria for the assessment of G feature 
defined by ENETS in 2006 were subsequently adopted 
by the WHO, which resulted in the ENETS/WHO 2010 
integrated system for the assessment of histological 
grading of NENs. 
Table VI presents two methods for assessing the 
histological malignancy grading of NENs, based on the 
number of mitotic figures counted in ten high-power 
fields with magnification of 400 x (1 HPF = 2 mm2), and 
the Ki-67 proliferation index determined by immuno-
histochemical analysis of the MIB1 antigen expression, 
calculated as the number of cells per 2,000 cells studied 
in the field containing cells with the highest staining in-
tensity (hot-spot), according to ENETS guidelines. Where 
the assessment by these two methods provides different 
grades for the tumour, the higher grade should be ac-
cepted. This division of NENs into two groups forms the 
basis for classification systems and therapeutic choices 
for this group of neoplasms [23, 29, 30].
The WHO 2010 classification system introduced the 
division of NENs into two basic categories, significantly 
different with regard to diagnostics, clinical behaviour 
and treatment. This division is presented in Table IV. 
The first group comprises well-differentiated neoplasms 
(formerly carcinoids) NEN G1 and NEN G2, made up of 
cells resembling normal neuroendocrine cells, expressing 
neuroendocrine markers, usually demonstrating exten-
sive synaptophysin and CgA expression, with hormonal 
expression dependent on the tumour location, and a small 
and medium nuclear atypia, below 20 mitotic figures/10 
HPF. Tumours in this category are classified and treated 
according to the criteria applicable to NEN [31, 32].
Another group, poorly differentiated and highly 
malignant neoplasms, NECs, are composed of small or 
large cells, only sometimes creating structures similar to 
neuroendocrine ones; they demonstrate an intense and 
extensive expression of synaptophysin, with a weaker 
expression of chromogranin A, marked nuclear atypia, 
necrosis and over 20 mitotic figures/ 10 HPF. The syn-
onymous terms are small cell or large cell neuroendo-
crine carcinoma, or poorly differentiated carcinoma. 
Table III. False-positive and false-negative results of daily urinary 5-HIAA excretion [13, 17, 18]
Tabela III. Fałszywie dodatnie i ujemne wyniki oznaczania dobowego wydalania 5-HIAA w moczu [13, 17, 18]
False-positives False-negatives
Food products rich in tryptophan: avocado, bananas, kiwi, 
pineapples, walnuts, plums, aubergine, cheese.
Discontinue 3 days before the collection
Food products: ethanol
Medicines: paracetamol, phenobarbital, ephedrine, certain 
cytostatics (cisplatin, 5-fluorouracil)
Discontinue 3 days before the collection
Medicines: neuroleptics, MAO inhibitors, methyldopa, isoniazid, acetylsalicylic acid, 
heparin, tricyclic antidepressants
Discontinue 3 days before the collection
Renal failure
Abnormal urine acidification
During the sample collection, add 10 mL of 25% HCl to urine, to reduce the pH to 
1.5–4.0.
Incorrectly collected daily urine sample
(determination of daily creatinine excretion, plastic containers, stored in a fridge)
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Table IV. WHO classification systems for neuroendocrine neoplasms introduced in 1980, 2000 and 2010
Tabela IV. Klasyfikacje WHO nowotworów neuroendokrynnych w roku 1980, 2000 i 2010
WHO 1980 WHO 2000 WHO 2010
I. Carcinoid 1. Well-differentiated neuroendocrine tumour  
— WDET
2. Well-differentiated neuroendocrine carcinoma 
— WDEC
3. Poorly differentiated neuroendocrine carcinoma 
— PDEC
1. G1 neuroendocrine neoplasm/tumour 
(carcinoid) (NEN/NET G1)
2. G2 neuroendocrine neoplasm/tumour (NEN/
NET G2)
3. Neuroendocrine carcinoma (NEC), large cell 
or small cell type
II. Mucocarcinoid
III. Mixed forms carcinoid-adenocarcinoma
4. Mixed exocrine-endocrine carcinoma — MEEC 4. Mixed adenoneuroendocrine carcinoma — 
MANEC
IV. Pseudotumour lesions 5. Tumour-like lesions — TLL 5. Hyperplastic and preneoplastic lesions
2.2.2. Obligatory and conditional methods of 
pathomorphological examination in NENs
The ENETS guidelines present the rules for exami-
nations of the sample, depending on its type. Fine-
needle aspiration biopsy is not recommended as 
a diagnostic method in the case of a non-diagnosed 
primary tumour. It may be used to confirm the 
presence of metastasis from the established point of 
origin [37–39]. 
The principles of preparation of the biopsy sample 
from the primary tumour or from metastases, and of 
the surgical tissue specimen, are presented below in 
Tables VII and VIII.
Minimal consensus statement on pathomorphological 
examination:
1. In the pathomorphological diagnostics of a small biopsy 
(excision from the lesion), it is recommended to diagnose the 
type of neoplasm, well-differentiated — NEN, or poorly dif-
ferentiated — NEC, MANEC — neuroendocrine tumour/ 
/neoplasm, and the grade (G1, G2 in NENs). TNM staging 
of the neoplasm is also recommended in the diagnostics of 
polyps with the morphology of NENs or a biopsy from liver, 
with established original tumour site, or to complete the data 
from imaging examinations. Pathomorphological diagnosis of 
NENs should always be confirmed by immunohistochemi-
cal examination, including the assessment of expression of 
chromogranin A, synaptophysin and the Ki-67 proliferation 
activity with MIB1 antibody.
2. Minimal histopathological report for the NEN surgical 
tissue sample should include:
— clinical data: tumour anatomical location and size, 
and clinical symptoms in the case of functional neoplasms;
— macroscopic features: tumour description including its 
location, cross-section appearance, relation to the surround-
ing tissue and surgical margins, according to the guidelines 
for the organ;
— microscopic features: description of the histoformative 
tumour structures and determination of the cell type, deter-
Table V. NENs classification system according to 2010 WHO 
Tabela V. Klasyfikacja nowotworów neuroendokrynnych 
według WHO z 2010 roku
Morphological 
differentiation grade
Malignancy (grade)
Well-differentiated Low grade, ENETS G1, NEN G1
Intermediate grade, ENETS G2, NEN G2
Poorly-differentiated High grade, ENETS G3, NEC
Table VI. Criteria for the assessment of grading of neuroen-
docrine tumours (G)
Tabela VI. Kryteria oceny stopnia histologicznej dojrzałości 
nowotworów neuroendokrynnych (cecha G)
Histological malignancy 
grade of NEN (G)
Mitotic activity/
number of mitotic 
figures/10 HPF
Ki-67 proliferation 
index/% of cells  
(per 2,000 cells)
G1 — well-differentiated,  
of low malignancy
< 2 ≤ 2
G2 — intermediate 
differentiation,  
of medium  
malignancy
2–20 3–20
G3 — poorly 
differentiated,  
of high malignancy
> 20 > 20
They are classified according to the criteria for classical 
cancers occurring in the specific organ. They are treated 
following the general oncological guidelines.
The next group consists of neoplasms referred 
to as MANEC. They are characterised by a complex 
structure, containing two components: glandular 
and neuroendocrine, and at least 30% content of 
a given component determines its diagnosis. The 
diagnosis of this type of neoplasm is confirmed by 
immunohistochemical examinations with the use of 
particular antibodies [33–36].
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mination of feature G based on the Ki-67/MIB1 proliferation 
index, and of mitotic index according to the ENETS/WHO 
system (G1-G3), studied in the regions of the highest activ-
ity (hot-spot);
— description of histopathological parameters of tumour 
invasion: angiolymphatic invasion, nerve infiltration, pres-
ence of necrosis, invasion of the tumour capsule (pseudo-
capsule) and determination of the depth of infiltration into 
the intestinal wall or adjacent tissue and organs;
— determination of imunohistochemical expression: ob-
ligatory chromogranin A, synaptophysin and Ki-67/MIB1, 
and conditionally, as ordered by clinicians, other hormonal 
markers;
— description of the tumour metastases, if present;
— description of surgical margins;
— description of other parameters, if present, such as 
inflammation, another neoplastic component.
3. Diagnosis (pathomorphological diagnosis)
Histopathological report should end with a diagnosis 
containing the following parameters:
— obligatory type of the neoplasm according to the World 
Health Organisation’s 2010 classification system;
— obligatory histological grade (G) according to the 
ENETS/WHO 2010 guidelines;
— obligatory pTNM pathological staging according to 
the ENETS and/or TNM AJCC/UICC criteria, with the year 
of edition; 
— margins polypectomy or surgical margins;
— assessment of the dominant cell type (for example, B if 
insulin is secreted, G for gastrin, EC for serotonin);
— suggested original tumour sites in cases of hepatic 
tumours or metastases to the lymph nodes with unknown 
original NENs location (*evidence level 3).
2.3. Location diagnostics
Diagnostic imaging of NENs is associated with a range 
of difficulties due to their small size, often atypical lo-
cation, and non-specific clinical symptoms. Therefore, 
it is necessary to use different imaging methods, both 
anatomical and functional.
The anatomical imaging methods include: 
 — ultrasonography (USG), especially endoscopic ul-
trasonography (EUS),
Table VII. Principles for examination of cytological and 
histopathological tissue specimens in neuroendocrine 
neoplasms
Tabela VII. Zasady badania materiału cytologicznego 
i histopatologicznego w nowotworach neuroendokrynnych
Type of material tested Recommendations, assessment 
methods
FNA — fine-needle aspiration In metastases with an established 
primary tumour site
Biopsy from the primary 
tumour or from metastases  
(liver, lymph nodes), surgical 
material
Biopsy sample preserved in formalin;
the preparation directly undergoes the 
process of technical preparation 
(without macroscopic assessment)
Conditional:
Recommended freezing of a tumour 
fragment before preservation in formalin
Obligatory:
Tissue specimen preserved in formalin, 
examined macroscopically, undergoes 
the process of technical preparation for 
microscopic preparations
Table VIII. Principles of macroscopic examination of surgical 
NENs material
Tabela VIII. Zasady badania makroskopowego materiału 
operacyjnego NEN
Macroscopic examination of surgical NENs material
Obligatory:
— determination of: location, number of tumours, size (three 
dimensions)
— assessment of tumour cross-section appearance: solid/cystic, 
necrosis present
— assessment of tissues surrounding the tumour/invasion of adjacent organs
— marking surgical margins with ink
— excision of lymph nodes
Conditional:
— obtaining and preservation of a fresh fragment of the tumour for 
scientific research,
Immunohistochemical examination
Obligatory:
— Immunohistochemical assessment of neuroendocrine markers: 
synaptophysin, CgA
— Immunohistochemical assessment of Ki-67/MIB1 proliferative 
activity
Conditional:
Immunohistochemical examination of hormonal expression (insulin, 
gastrin, serotonin and other) if the symptoms of tumour hormonal 
activity occur:
— assessment of metastases of functional tumours to the liver or 
lymph nodes if the original tumour site is unknown
— confirmation of the clinical symptoms of functional tumours
 — immunohistochemical assessment of somatostatin receptors (e.g. 
SSTR2) for therapeutic purposes
— immunohistochemical assessment of vascular markers expression 
in order to examine angioinvasion
* evidence level according to CEBM [145]
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 — computed tomography (CT),
 — magnetic resonance imaging (MR),
 — endoscopy,
 — capsule endoscopy.
Classical imaging methods (i.e. CT, USG, MR) are 
useful primarily in the assessment of the stage of the 
disease, and monitoring of the response to treatment. 
They also play an important role in planning the surgi-
cal management of the primary tumour. Moreover, they 
enable performing a fine-needle or large-needle biopsy. 
Over the last few years, endoscopic techniques have 
been developed significantly. Their accessibility has also 
increased. Today, these methods enable conducting 
both diagnostic and therapeutic procedures.
An important achievement in the diagnostics of 
NENs was the introduction of scintigraphic examina-
tions demonstrating the expression of somatostatin re-
ceptors (SRS, somatostatin receptor scintigraphy). These 
are functional tests, which enable the characterisation 
of lesions on the molecular level. 
Another important achievement has been the recent 
introduction of somatostatin analogues labelled with 
a positron radiation emitter — 68Ga: 68Ga-DOTA-D-
Phe1,Tyr3-Octreotide (68Ga-DOTATOC), 68Ga-DOTA-D-
Phe1,Tyr3-octreotate (68Ga-DOTATATE) and 68Ga-DOTA-
1-NaI3-Octreotide (68Ga-DOTANOC) to the PET/CT 
examinations. Tests using these radiopharmaceuticals 
demonstrate a higher sensitivity in the diagnosis of 
primary tumours, as well as osseous and pulmonary 
metastases. 
The combined use of morphological and functional 
imaging techniques has allowed increases in the sensitiv-
ity and specificity of diagnostic methods in NEN [40–43]. 
Both morphological and functional examinations 
are used in:
 — assessment of the extension of the disease,
 — localisation of the primary tumour,
 — planning the surgical treatment,
 — assessment of the response to treatment,
 — qualification for radioisotope therapy.
2.3.1. Ultrasonography
Transabdominal ultrasonography
USG examination, due to its high availability and low 
cost, is usually the first imaging test performed. The 
sensitivity of the test depends on the tumour location, 
the experience of the doctor conducting the examina-
tion, and anatomical and technical conditions [34]. 
In clinical practice, a USG examination is used 
mostly in preliminary diagnostics of pancreatic endo-
crine tumours and hepatic metastases. 
Due to technical limitations, USG is not useful in the 
assessment of other parts of the gastrointestinal tract. 
The image of NEN in a USG examination is non-
specific. The tumour is often well-circumscribed, 
hypoechogenic, sometimes with a hyperechogenic 
capsule, foci of necrosis, and calcifications. However, the 
tumour may also be hyperechogenic or isoechogenic. 
Most tumour foci in a Doppler examination demon-
strate rich vascularisation. 
The sensitivity of transabdominal USG in the diag-
nostics of metastatic foci in the liver ranges from 82% 
to 88%, and specificity is between 92% and 95% [44]. 
The method’s sensitivity in the diagnosis of pancreatic 
tumours is much lower — 39% (17–79%) [38, 45–50]. 
Using contrast medium in ultrasonographic diag-
nostics (contrast enhanced ultrasonography, CEUS) 
is very useful; 78–86% of tumour foci demonstrate 
contrast enhancement in the arterial phase. The sensi-
tivity of CEUS in the diagnostics of hepatic metastases 
increases to 99% [51].
Endoscopic ultrasonography
Presently, the basic examination in the diagnostics of 
NENs of the pancreas (PNENs) and rectum is endo-
scopic ultrasonography (EUS). The small distance be-
tween the source of ultrasounds and the object studied 
enables the use of ultrasonic waves of higher frequency 
than in a conventional USG device. This results in much 
better image resolution. 
The accepted indications for EUS include the as-
sessment of local advancement of neoplastic lesions 
located within the gastrointestinal tract, including the 
diagnostics of submucosal lesions and diseases of the 
pancreas and bile ducts, together with the assessment 
of the lymph nodes. The examination enables the 
demonstration of a small-volume lesion, a few tumour 
foci, the tumour within the duodenal wall, and the 
assessment of the regional lymph nodes. This method 
allows the precise determination of anatomical relations 
(i.e. tumour location relative to the bile ducts and main 
vessels), and primarily, an assessment of the depth of 
the gastrointestinal wall infiltration. 
EUS examination is particularly useful for the diag-
nosis of pancreatic NENs (due to their typically small 
size). The method’s sensitivity depends on the location 
of the tumour: for tumours located in the head and 
body of the pancreas, it is approximately 90% (77–100%) 
[39–46]; for tumours located peripherally it is 75–80% 
[45, 46]. The specificity of the method is estimated at 
95% [46]. In the diagnostics of the neoplastic foci located 
in the pancreas in high-risk patients, EUS is more sensi-
tive than CT [52].
* evidence level according to CEBM [145]
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Transrectal EUS is the most sensitive method of 
pre-operative assessment of the stage of rectal tumour 
advancement; its sensitivity in the assessment of the 
tumour and invasion of the rectum wall is 76–93%, and 
of the regional lymph nodes metastases it is 61–88% [53]. 
Intra-operative ultrasound
Intra-operative ultrasonography (IOUS) is used pri-
marily to diagnose focal lesions in the pancreas. The 
sensitivity of this technique is 90% (74–96%), especially 
in combination with intra-operative palpation assess-
ment [42, 54, 55].
Intraductal ultrasonography
Mini-probes may be introduced through the endoscope 
biopsy channel into the pancreatic duct or bile duct. 
This technique enables the assessment of the inside of 
the duct and its wall (intraductal sonography, IDUS). 
It allows better, compared to EUS, visualisation of pan-
creatic NEN in the immediate vicinity of the pancreatic 
duct, and of the endo-luminal lesions. Sensitivity of this 
examination is approximately 94% [56], and it increases 
to almost 100% for the lesions larger than 3 mm, located 
in the pancreatic duct [57].
2.3.2. Endoscopic examinations
Upper gastrointestional endoscopy (oesophago-gastrodu-
odenoscopy) or colonoscopy with ileoscopy are frequently 
the first examinations to be performed in patients with 
suspected or diagnosed NENs. Endosocpy is the best 
method for evaluation gastric and duodenal NENs. It is 
worth emphasising that they are usually found acciden-
tally. These tumours are usually in the form of polypoid 
mucosal elevation, and only histopathological examina-
tion enables a proper diagnosis [58].
Video Capsule Endoscopy (VCE), Wireless Endoscopy — is a 
non-invasive examination of the small intestine performed 
with a single-use, wireless capsule swallowed by the 
patient. The capsule passively moves through the gastro-
intestinal tract, allowing assessment of the small intestinal 
mucosa along its entire length. This examination does not 
substitute gastroscopy or colonoscopy. Unlike a traditional 
endoscope, the capsules used presently are not steerable, 
so another more precise assessment of a chosen part of 
the intestine is impossible. 
The limitation of this technique is the run-time of 
the battery inside the capsule (eight hours). Therefore, 
in some patients with disturbed peristalsis, the distal 
part of the ileum may remain unexamined.
The most common complication (0.75% of all pa-
tients, 1.25% of patients with Crohn’s disease) is capsule 
incarceration in the small intestine, most frequently in 
the narrowing of the intestine resulting from the use of 
anti-inflammatory medicines or due to other diseases.
Present reports indicate a relatively low sensitivity 
of the test with the use of an endoscopic capsule in the 
detection of midgut lesions, especially in the detection 
of submucosal and eccentric lesions; the sensitivity is 
approximately 45%. Small intestinal tumours are di-
agnosed mostly by accident, during diagnostics of e.g. 
gastrointestinal haemorrhage [59].
Another diagnostic method which enables the 
assessment of the small intestine and obtaining the 
material for histopathological examination with the 
possibility of endoscopic treatment is balloon enteroscopy 
(single-balloon, double-balloon) or spiral enteroscopy.
While conducting the examination, it is possible to 
use simultaneously endoscopic ultrasonography (EUS) 
with miniature heads whose external diameter is 2 or 
2.6 mm, introduced through the enteroscope biopsy 
channel [60].
Enteroscopy enables visualisation of 177–270 cm 
of the small intestine in transoral examination and ca. 
150 cm in transrectal examination [61, 62]. The exami-
nation takes 20-240 minutes [63]. Capsule endoscopy 
and balloon enteroscopy are complementary methods. 
Non-invasive capsule endoscopy enables initial localisa-
tion of the tumour focus, whereas enteroscopy helps to 
obtain material for histopathological examination and 
conducting therapeutic procedures [64, 65].
A complete assessment of the small intestine is 
achieved in approximately 80% of patients, and diag-
nostic efficacy of the examination is ca. 55% [61].
2.3.3. Computed tomography 
Computed tomography examination is presently the 
standard method in assessment of the location of 
tumour foci and determination of the NEN stage [34]. 
CT is also used to monitor the effects of treatment. 
However, this examination demonstrates relatively 
low sensitivity in locating the primary tumour site [34]. 
Currently, spiral MDCT — multidetector computed 
tomography — devices are in common use. Depending 
on the manner of filling the gastrointestinal lumen, the 
examination is referred to as CT enterography if the 
patient receives low-absorption contrast material, or CT 
enteroclysis if it is administered using a probe introduced 
into the small intestine. After proper filling of the gastro-
intestinal tract, a CT examination is performed before and 
after the administration of contrast material. Scanning 
after intravenous administration of the contrast material 
should be conducted in two phases — arterial and portal 
venous, comprising all the intestines and the liver — to 
detect possible metastases).
Symptoms indicating malignancy of the tumour 
include: large volume, necrosis, characteristics of 
infiltration of adjacent tissues (lesions occur in ap-
proximately 20% of patients). In the arterial phase, 
hyperdense lesions are most frequently found, but more 
rarely they are hypovascularised or cystic. In the portal 
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venous phase, NENs are mostly hypodense lesions, as 
the contrast material is quickly washed out from them.
The sensitivity of the CT examination in the diagnos-
tics of pancreatic tumours is 73% (63–82%), and speci-
ficity is 96% (83–100%) [66–69]. The test’s sensitivity in 
the assessment of hepatic metastases is 82% (78–100%), 
and specificity is 92% (83–100%) [38, 70, 71]. In the di-
agnostics of extrahepatic metastases, the sensitivity of 
CT examination is 75% (63–90%), and specificity is 99% 
(98–100%) [38, 66, 67]. 
CT colonography
Computed tomography also enables virtual colonos-
copy (VC) to be conducted. This method allows the 
production of three-dimensional images of the walls 
and content of the large intestine. To obtain perfect 3D 
reconstructions, it is necessary to perform the examina-
tion using a submillimetre layer. 
The patient requires proper preparation, similarly 
to traditional colonoscopy. The preparation consists in 
complete emptying of the large intestine from faecal 
masses and liquid (residual faecal masses may result 
in false-positives) [72–74]. 
Full assessment of the examination includes the 
analysis of topical scan and the axial cross-section im-
ages (treated as reference images), and the analysis of 
multiplanar and three-dimensional reconstructions 
(including 3D algorithms of navigator type). A novelty 
that improves the effectiveness of results interpretation 
is computer aided diagnosis (CAD). 
CT colonography is a safe and well-tolerated diag-
nostic method. The sensitivity and specificity of the 
method are comparable with classical colonoscopy. 
The sensitivity of CT and endoscopic colonography is 
similar; according to different authors, it is 90% for lesions 
> 10 mm, and 85 % for lesions > 6 mm; the sensitivity and 
specificity in the diagnostics of malignant neoplasms is 
88–100%, and in benign neoplasms it is 86% [75, 76]. 
The quality of the obtained images depends on 
patient co-operation and preparation [77].
2.3.4. Magnetic resonance imaging
The sensitivity and specificity of magnetic resonance 
imaging (MR) are similar to CT in the diagnosis of the 
primary focus and metastases of NENs [78]. The exami-
nation protocol includes performance of the following 
images/sequences:
 — T1-weighted (spin-echo, SE),
 — T1-weighted with fat saturation,
 — T1-weighted (gradient echo, GRE) after administra-
tion of the contrast material (dynamic and static 
examination),
 — T2-weighted (fast spin-echo, FSE),
 — T2-weighted with fat saturation [79],
 — DWI with ADC mapping. 
Tumours demonstrate a hypointense signal in 
T1-weighted images, and a hyperintense signal in 
T2-weighted images (rarely hypointense — if they 
contain a large fibrous tissue component), and they 
are visibly enhanced after administration of the con-
trast material. Cystic tumours with necrotic foci are 
ring-enhanced. 75% of metastatic foci in the MR scan 
demonstrate a hypointense signal in T1-weighted 
images, most of them are strongly enhanced after 
administration of contrast material. The MR technique 
also enables conducting of a CT colonography-type 
examination. The advantages and disadvantages of 
this method are similar to CT colonography. 
MR imaging — following the optimal protocol — al-
lows the diagnosis of 80–95% of metastatic foci in the 
liver [34, 67, 76, 80], and 73–93% of pancreatic NENs 
[25, 34, 36]. In the diagnostics of extra-pancreatic and 
extra-hepatic foci, the test’s sensitivity is much lower, 
i.e. 68–89% [34, 67]. 
Whole-body MR imaging is considered to be 
a second-line test in the assessment of hepatic metasta-
ses smaller than 10 mm, and in the assessment of foci 
with non-specific enhancement on the CT scan. It is 
also recommended in patients allergic to iodine contrast 
material used in CT scanning. 
2.3.5. CT/MR enteroclysis/enterography
Presently, to assess the small intestine, CT/MR enterog-
raphy/enteroclysis are used (see above). These methods 
increase the CT sensitivity to 86–97% [3, 81]. 
The techniques enable identification of even small, 
segmental thickening of the intestinal wall, small nod-
ules in the intestinal wall, and segmental narrowing 
of the lumen. MRI examination provides better tissue 
resolution than CT; it enables assessment of intestinal 
wall layers and of the level of its infiltration by the tu-
mour. The scope of the examination should include the 
field from the level of the liver to the pubic symphysis. 
In CT/MR enteroclysis, contrast medium is admin-
istered through a probe introduced under fluoroscopic 
control beyond the duodenojejunal angle. An anti-reflux 
balloon prevents reflux of the contrast material into the du-
odenum. After the contrast material has been administered, 
MR examination of the abdominal cavity is performed, 
using a surface coil. Fast T1-weighted and T2-weighted 
sequences should be performed (HASTE, FIESTA), as well 
as T2-weighted sequences with fat saturation, and exami-
nation after intravenous administration of contrast mate-
rial (T1-weighted images). The layers should be 3–5 mm 
thick. As a standard procedure, the patient should be in 
the supine position (the prone position is uncomfortable, 
and the patient cannot stay in it for long; therefore, it is 
rarely used, e.g. if artefacts are present). In CT enteroclysis, 
intravenous contrast material is administered, 1.5–2 mL/kg, 
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at 3–4 mL/s, the test is performed with 30–60 s delay (from 
45 seconds — intestinal phase), and the layers should be 
1.25–2.5 mm thick [82].
In MR/CT enterography, the contrast medium is 
administered orally an hour before the examination. 
Intravenous administration of medicines slowing in-
testinal peristalsis is recommended. 
Enteroclysis provides a better level of extension of 
the intestinal loops, and the ability to assess peristalsis; 
however, patient tolerance of the test is lower compared 
to enterography. Sensitivity of CT enterography and 
enteroclysis is similar. Due to a long time of data acquisi-
tion in the MR imaging, enteroclysis is recommended 
in this test [79]. 
The examination time in CT enteroclysis is shorter than 
in MR enteroclysis. Therefore, the quality of the test is less 
dependent on co-operation with the patient. However, it 
is associated with patient exposure to ionising radiation. 
Diagnostics of small intestine diseases should in-
volve CT enterography or MR enterography. For the 
follow-up of small intestine diseases, MR enterography 
should be applied.
MR enteroclysis should be performed in patients 
with negative MR/CT enterography results and with 
clinical symptoms of small intestine diseases (Table IX).
Minimal consensus statement on imaging tests:
The choice of imaging examination depends on the pri-
mary focus location and the stage of the disease: USG, CT, 
MRI, endoscopy (*evidence level 3–4).
Individual GEP NENs are discussed in detail in other 
sections of our recommendations.
2.4. Radioisotope diagnostics
2.4.1. Isotope diagnostics using isotope-labelled 
somatostatin analogues
Isotope diagnostics using isotope-labelled somatostatin 
analogues is the most sensitive method of the diagnostic 
imaging of NENs. The sensitivity of somatostatin recep-
tor scintigraphy (SRS) is approximately 80–90% [83] for 
most types and locations of GEP NENs. Insulinoma is 
an exception, probably due to a lower somatostatin re-
ceptor expression. Clinical indications for SRS include: 
localisation of the primary focus, determination of the 
stage of the disease, monitoring of the patient following 
a radical surgical treatment, and qualification of patients 
for treatment with ‘cold’ and ‘hot’ SSA.
2.4.2. Isotope diagnostics with the use  
of 111In-OctreoScan
In 1994, the USA Federal Drug Administration (FDA) au-
thorised indium-labelled 111DTPA0-D-Phe1-octreotide 
(111In-OctreoScan®, pentreotide) for marketing. This 
compound demonstrates a high affinity to SST2 (IC50 
2 nM), a much lower affinity to SST5 (22 nM) and SST3 
(IC 50 187 nM), and no affinity to SST1 and SST4 [81]. In 
a multicentre study, the sensitivity of receptor scintigra-
phy with the use of pentreotide was approximately 80% 
[84], including 100% for glucagonoma, 89% for VIP, 87% 
for carcinoid and 82% for non-functional pancreatic 
tumours. Presently, due to the higher sensitivity of tests 
with other tracers, in most centres the use of 111-In-
OctreOscan has been renounced (*evidence level 3).
2.4.3. Diagnostics with the use of technetium-
labelled SSA (99Tc)
Technet-labelled SSA are increasingly often used in 
the isotope diagnostics of NENs [85–88]. The physical 
properties of technetium increase the number of counts 
detected and the quality of scintigraphy. Similarly to 
pentreotide, the highest sensitivity is achieved with the 
SPECT technique. Due to the positive Polish experience 
with (99Tc-EDDA/HYNIC) octreotate–tectreotide — in-
dicating a high sensitivity of scintigraphy [85], scintig-
raphy with the use of pentreotide has been completely 
substituted by this method, especially in centres which 
do not offer positron emission tomography (*evidence 
level 3).
Table IX. Sensitivity and specificity of imaging examinations in the diagnostics of GEP NENs [38]
Tabela IX. Czułość i swoistość badań obrazowych w diagnostyce GEP NEN [38]
Type of examination CT (sensitivity/specificity) MRI (sensitivity/specificity) USG (sensitivity/specificity)
Pancreatic endocrine tumours 73%/96% 93%/88% 93%/95% (EUS)
Hepatic metastases 82%/92% 80–95% 88%/95%
Metastases outside the liver to soft tissues 75%/99% 89%/100% –
Small intestinal lesions 50%/25%
85%/97% (enteroclysis)
– –
* evidence level according to CEBM [145]
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2.4.4. Diagnostics with the use of positron emit-
ting tracer-labelled SSA
Scintigraphy using positron emitting tracers is an 
imaging method characterised by the highest resolu-
tion among all the isotope examinations. Literature 
data suggests higher sensitivity of scintigraphy with 
somatostatin analogues labelled with positron emitting 
tracers (68Ga) compared to the SPECT test with 111In-
pentreotide [89]. The sensitivity, specificity and diag-
nostic accuracy in PET examinations using 68Ga-labelled 
SSA are 97%, 92% and 96%, respectively [40, 90]. In over 
50% of patients with neuroendocrine neoplasms, the 
PET examination affects a change of the disease stage, 
and determines further treatment [99].
There is no comparative data on 99Tc radiopeptides. 
In centres with a PET scanner, examination with 68Ga 
should be the test of choice (*evidence level 3).
2.4.4. Isotope diagnostics with the use of 18F-FDG
The 18FDG — PET/CT examination (fluorodeoxy-
glucose) is usually negative in well-differentiated 
NENs, mainly G1 NENs [92, 93]. However, it has been 
demonstrated that collection of 18FGD in neoplastic 
foci is a negative prognostic factor [90]. The PET/CT 
scan with 18FDG, and the assessment of somatostatin 
receptor expression in a 68Ga- PET/CT is useful in 
qualification for radioisotope treatment, particularly 
in NENs G2 [94].
2.4.5. Isotope diagnostics with 18F-DOPA
PET diagnostics with the use of 18F-DOPA tracer 
(18F-DOPA-PET) is a new, promising method of NEN 
imaging. In the diagnosis of NEN, 18F-DOPA-PET has 
demonstrated a sensitivity of 89%, compared to 56% 
for CT and 47% for SRS [95].
2.4.6. Diagnostics with the use of m-IBG
Another tracer used in the diagnostics and therapy of 
NEN is m-IBG (metaiodobenzylguanidine). Imaging 
with the use of 123/131m-IBG is performed primarily in 
pheochromocytoma and neuroblastoma, rarely in 
the case of other neoplasms of neuroendocrine dif-
ferentiation. The sensitivity of m-IBG scintigraphy in 
NEN is approximately 70% (40–85%), and it is lower 
than that of the test with 111In-pentreotide [96]. The 
best results are achieved using 123m-IBG in visualisa-
tion of hepatic metastases. However, also in this case 
receptor scintigraphy is more sensitive [97]. Therefore, 
presently m-IBG scintigraphy is justified in patient 
qualification for isotope treatment if receptor scintig-
raphy is negative.
In addition to these radiomarkers, research is cur-
rently being conducted into other tags receptors: GLP1 
analogues, gastrin, and bombesin. 
Minimal consensus statement on radioisotope tests:
 — receptor scintigraphy (SPECT/CT) with labelled somato-
statin analogue (in Poland: labelled with technetium) or 
68Ga-PET/CT in G1 and G2 NENs (*evidence level 3);
 —  18FDG-PET/CT in NECs (in individual cases for G2, G1 
NENs) (*evidence level 4).
3. Treatment
3.1. Surgical treatment
In GEP NENs, the treatment of choice is surgical man-
agement. Its scope depends on the patient’s general 
condition and on the location, stage and specificity 
(biology) of the neoplasm (*evidence level 4) [8, 98]:
1. Therapy with the intention to cure (radical) — 
resection.
2. Cytoreductive therapy (reduction of the tumour 
mass by ca. 90%).
3. Palliative therapy (improvement of the quality 
of life):
— management of metastases:
• resection,
• ablation,
• embolisation,
• transplantation;
— management of mechanical jaundice:
• by-pass,
• prosthesis;
— management of obstruction of the gastrointes-
tinal tract:
• palliative resection,
• by-pass;
— management of gastrointestinal bleeding;
— pain management (e.g. solar plexus neurolysis).
The varied biology and clinical picture of GEP NENs, 
compared to the most frequent gastrointestinal adenocar-
cinomas, affects the methods of treatment and indications 
for surgical management, discussed in detail for different 
parts of the gastrointestinal tract in further sections of this 
document. The same principles of oncological manage-
ment apply to NENs, especially to malignant forms (high 
level of cell proliferation, possible metastases to other 
organs), as to other malignant neoplasms. 
They include:
1. Diagnostics and staging.
2. Treatment, including combined therapy (neoad-
juvant, inductive, adjuvant, palliative).
* evidence level according to CEBM [145]
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3. Monitoring of the effects of treatment (oncologi-
cal supervision). 
The principles of GEP NEN treatment are pre-
sented in Figure 2 [101]. This scheme applies primarily 
to poorly-differentiated neuroendocrine carcinomas. 
In clinical stages I, II and III, treatment with the inten-
tion to cure, i.e. radical treatment, may be considered. 
In stage IV clinical advancement, when the neoplasm 
reaches the systemic scope (presence of distant metas-
tases, e.g. in the liver, lungs), palliative therapy may 
be introduced in order to improve the quality of life 
(e.g. somatostatin analogues, pain management) and/ 
/or extend the survival (e.g. surgery, chemotherapy, 
radioisotope therapy — individual or combined). In 
the case of well-differentiated NENs, radical resection 
may also be considered, if there are liver metastases [99, 
100]. Similarly, as in colonic cancer, radical resection of 
the primary tumour and hepatic metastasis may result 
in a complete curative effect. In the case of resectable 
primary and metastatic tumours, aggressive radical 
surgery is the best therapeutic option. In stage IV G1-G2 
GEP NENs which feature M1 in the liver, the surgical 
procedure does not have to be tantamount to palliative 
treatment [97]. Resection of the metastases should be 
accompanied by removal of the regional lymph nodes 
[97]. The principles of the treatment of NEN metastases 
to the liver are presented in Figure 3 [97].
Palliative surgical treatment of NENs may consist 
of treating the obstruction of the gastrointestinal tract 
(by-pass, palliative resection), management of gastro-
intestinal bleeding (argon plasma coagulation — APC, 
laser therapy, palliative resection), management of 
metastases, including: resection, ablation (e.g. radiof-
requency thermoablation [RFA]), embolisation, and liver 
Figure 2. Treatment principles for gastrointestinal malignant tumours according to disease UICC (Union Internationale contre le 
Cancer) staging [101]
Rycina 2. Zasady leczenia złośliwych nowotworów układu pokarmowego w zależności od stopnia klinicznego zaawansowania według 
klasyfikacji Międzynarodowej Unii Przeciwrakowej (UICC, Union Internationale contre le Cancer) [101]
Figure 3. Treatment principles for NEN metastases to the liver [99]
Rycina 3. Zasady leczenia przerzutów NEN do wątroby [99]
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transplant. A specific form of palliative treatment of 
NEN is cytoreductive therapy, which consists in re-
duction of the neoplasm mass by ca. 90%, and further 
systemic management (chemotherapy), or biotherapy 
(SSA, interferon alpha [INF]). 
Aspects related to the treatment of NEN include [12]:
1. Epidemiological conditions — rare neoplasms 
(approximately 2% of gastrointestinal neoplasms).
2. Diagnostic conditions:
— early cases are rare;
— single tumours occur sporadically;
— multiple tumours are multi-focal, or occur in 
multiple endocrine neoplasia (MEN) syndromes.
3. Biological conditions:
— functional tumours (approx. 20%);
— non-functional tumours;
— low proliferation index.
4. Oncological conditions:
— benign neoplasms are less common;
— malignant neoplasms are more common;
— prognosis, regardless of the character of the neo-
plasm (benign/malignant), is usually good.
Indications for liver transplantation in GEP — 
NENs
Treatment by liver transplant in patients with GEP 
NENs should be considered when non-resectable neo-
plastic lesions are found in the liver parenchyma, both 
primary and metastatic. This method of treatment is 
also indicated in patients with hepatic recurrence of the 
neoplastic disease, after liver resection, ablation therapy 
or systemic treatment due to GEP NEN. Liver transplant 
may be performed in the case of symptomatic or non-
symptomatic tumours [4 , 100, 102, 103].
Qualification for liver transplantation depends 
on confirmation of exclusively hepatic location of 
the metastases or the primary GEP NEN by imaging 
examinations (no extra-hepatic metastases), and on 
its histopathological grade G1 or G2 according to the 
WHO classification system [101, 104, 105] (*evidence 
level 3).
The risk factors for worse outcomes of the transplan-
tation (i.e. complications and recurrence), and thus for 
patient survival, include [101, 106, 107]:
A — primary tumour located in the pancreas or 
duodenum,
B — hepatomegaly,
C — gastrin-secreting tumour,
D — high proliferation activity (Ki-67 > 5%),
E — high metastatic activity (lowered E-cadherin),
F — recipient’s age > 55 years,
G — resection of extra-hepatic lesions during OLTx,
H — type III hepatic metastases of GEP NENs (mul-
tiple, diffused lesions in both lobes of the liver),
I — extensive multi-organ resection preceding OLTx.
The outcomes of the treatment by liver transplantation 
in this group of patients are considerably worse than in 
the group of patients with a better prognosis. One-year 
survival is achieved by 43–76% of patients, and five-year 
survival by 12% of patients. Re-surgery in the period im-
mediately after the operation is necessary in up to 35% of 
patients [101–103, 106–108] (*evidence level 3).
Factors improving the prognosis after OLTx include 
[101, 106–108]:
A — primary tumour location other than the pan-
creas or duodenum,
B — carcinoma,
C — possible oncologically radical resection (R0) 
prior to OLTx,
D — low proliferation activity (Ki-67 > 5%),
E — low metastatic activity (normal E-cadherin),
F — serotonin-secreting tumour,
G — recipient’s age < 50 years,
H —– no progression of the neoplastic disease 
within six months,
I — neoplasm infiltration of < 50% of hepatic pa-
renchyma,
J — absence of hepatomegaly.
In such a group of recipients, one-year survival may 
be achieved by 88–90% of patients, five-year survival by 
47–80% of patients, and ten-year survival by 28–50% of 
patients. Complications are found in 18–35% of patients, 
and the death rate is 4.5–17% of patients after the sur-
gery. An unresolved and still pressing problem is the 
recurrence of the underlying disease: within a year after 
liver transplantation, it affects 44% of patients, within 
three years 63%, and within five years 80% [101–103, 
106–108] (*evidence level 3).
Minimal consensus statement on surgical treatment:
In GEP NENs, the treatment of choice is surgical manage-
ment. Its scope depends on the patient’s general condition and 
on the location, stage and specificity (biology) of the neoplasm 
(*evidence level 4). Treatment options include resection with the 
intention to cure (radical), cytoreductive therapy (reduction of the 
tumour mass by approximately 90%), and palliative treatment.
 — In patients with the disease limited to a resectable primary 
lesion and regional lymph nodes, radical surgical treat-
ment is introduced with the intention to cure (*evidence 
level 4). In individual cases, particularly of G1-G2 NENs, 
in potentially resectable lesions with hepatic metastases, 
surgical resection should also be considered (resection of 
the primary and metastatic tumour) (*evidence level 4). In 
* evidence level according to CEBM [145]
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non-resectable primary tumours, cytoreductive or pallia-
tive procedures are performed. A selected group of patients 
with non-resectable hepatic lesions and uncontrolled 
symptoms which do not disappear after implementation 
of available treatment methods may be qualified for liver 
transplantation (*evidence level 3).
 — Liver transplant should be considered in patients with 
non-resectable G1 or G2 GEP NENs in the liver paren-
chyma, if PET-CT examination or diagnostic laparoscopy/ 
/laparotomy does not reveal metastases outside the liver. 
Another essential condition is the removal of the primary 
tumour before liver transplantation, and Ki-67 < 10% 
(*evidence level 3).
3.2. Endoscopic treatment
The main purpose of the treatment of GEP NENs is radi-
cal removal of the tumour, and in the case of functional 
tumours — control of the clinical symptoms associated 
with the production of specific hormones. 
Although the basic method of radical treatment is 
surgical resection, technological progress in endoscopic 
equipment plus the development of new therapeutic 
endoscopic techniques justify using this treatment in 
certain cases [108, 109]. 
This is possible mainly due to the introduction of 
methods such as endoscopic ultrasonography (EUS), 
which enables a precise assessment of the gastrointesti-
nal tract wall and its individual layers with surrounding 
structures, and adequate qualification of patients for en-
doscopic or surgical procedures, as well as endoscopic 
mucosal resection (EMR) and endoscopic submucosal 
dissection (ESD) [110].
The therapeutic approach in GEP NENs located 
in the upper gastrointestinal tract and in the large in-
testine, often detected during a diagnostic endoscopic 
examination, depends on the tumour size, depth of 
invasion and the presence of metastases at the diag-
nosis. Endoscopic resection of GEP-NET may be used 
as a treatment method only in well-differentiated G1 
and T1 tumours, according to the TNM classification 
system. Before deciding on endoscopic treatment, an 
endosonographic examination is necessary to deter-
mine the size of the lesion and the depth of infiltration 
into the gastrointestinal tract wall, as well as to assess 
the regional lymph nodes. The test may be completed 
with fine-needle biopsy of the primary lesion and 
lymph nodes. 
Only lesions limited to the mucosa and submucosa 
qualify for endoscopic removal, while in all other cases 
local or radical surgical excision is recommended, pos-
sibly with supporting therapy or chemotherapy. 
It is estimated that approximately 20% of gastric 
NENs, 10% of duodenal NENs, and as many as 70% of 
rectal tumours qualify for endoscopic removal. 
The following histopathological criteria confirm 
completeness of the endoscopic procedure results: 
complete removal of the lesion (negative margin), ab-
sence of angioinvasion, low mitotic activity, and low 
proliferative index.
In most cases, after the endoscopic treatment, fur-
ther supervision is recommended although its princi-
ples have not been clearly defined for all cases [111].
Classical polypectomy performed with the use 
of an electrocoagulation loop is not recommended 
as a  therapeutic method in GEP NENs, as it often 
leaves a positive margin after the procedure, so the 
optimal method is endoscopic mucosal resection. 
Endoscopic resection conducted by the injection and 
cut technique consists in lifting the lesion from the 
muscular layer of the wall by submucosal adminis-
tration of a substance (saline with adrenalin) which 
creates a ‘bubble’ under the lesion, and in subsequent 
removal of the lesion with a diathermic loop. Lift-
ing of the lesion is a condition for qualifying for this 
procedure; absence of this phenomenon (non-lifting 
sign) indicates infiltration of deeper layers of the gas-
trointestinal tract wall, and is a contraindication for 
endoscopic resection. Other EMR techniques include 
injection, lifting and section (strip biopsy), endoscopic 
mucosal resection with ligation (EMR-L) or cap as-
sisted endoscopic mucosal resection (EMR-C). Lesions 
limited to the mucosa, well-differentiated, convex, 
smaller than 2 cm and without ulceration qualify for 
endoscopic resection [112].
Endoscopic submucosal dissection is a technique 
which enables removing lesions even greater than 3 cm 
in diameter in one piece (en-bloc) within the normal 
tissue. It involves marking by means of electrocoagu-
lation of the mucosa surrounding the lesion, injecting 
solution into the submucosal membrane and lifting 
the lesion above the muscularis propria, performing 
circular dissection of lamina propria mucosa around 
the lesion, and removing the lesion together with the 
submucosal membrane [113].
The most common complication following mucosal 
resection and endoscopic submucosal dissection is 
haemorrhage (10–20%) and perforation (1%). They are 
more frequent in cases of duodenal or gastric lesions 
removal than in rectal lesions. ESD, compared to EMR, 
is characterised by a higher size-independent ratio 
of lesions removed en-bloc (OR 13.87), and a lower 
local recurrence ratio (OR 0.09), but this technique 
* evidence level according to CEBM [145]
433
Endokrynologia Polska 2013; 64 (6)
takes longer to perform and demonstrates a higher 
rate of complications (haemorrhage OR 2.2; perfora-
tion OR 4.09).
Endoscopic methods can also be used in palliative 
treatment of NEN in the case of:
 — mechanical jaundice due to obstruction of the biliary 
tree (stenting of the biliary tree);
 — obstruction of the gastrointestinal tract (stenting of 
the gastrointestinal tract);
 — gastrointestinal bleeding (endoscopic hemostasis);
 — pain (EUS-controlled celiac plexus neurolysis);
 — functional tumours with clinical symptoms (EUS-
controlled ablation).
Minimal consensus statement on endoscopic treatment:
 — In certain clinical situations (well-differentiated gas-
tric, duodenal and rectal G1 and T1 tumours, according 
to TNM classification), endoscopic methods such as 
endoscopic mucosal resection (EMR) and endoscopic 
submucosal dissection (ESD) may provide a beneficial 
alternative to surgical treatment. Endoscopic ultra-
sonography (EUS) enables precise assessment of the 
gastrointestinal tract wall and its individual layers 
with surrounding structures, as well as adequate 
qualification of patients for endoscopic or surgical 
procedures. 
 — Endoscopy also enables palliative treatment of mechanical 
jaundice due to obstruction on the biliary ducts, obstruc-
tion of the gastrointestinal tract, gastrointestinal bleeding, 
pain (EUS-controlled celiac plexus neurolysis) and — in 
special cases — ablation of functional tumours causing 
clinical symptoms (*evidence level 3).
3.3. Pharmacological treatment
3.3.1. Biotherapy: somatostatin analogues (SSA) 
and interferon
In most cases, radical surgical treatment of a neoplasm 
is impossible due to a late stage of the disease at the 
diagnosis [8, 114]. SSA play a major role in the phar-
macological treatment of GEP NENs [8].
A. Reduction of clinical symptoms and improve-
ment of the quality of life in patients with func-
tional tumours
SSA are the ‘gold standard’ in the treatment of func-
tional tumours; these medications reduce secretion of 
hormones and biologically active substances, control 
the symptoms of the disease, and significantly improve 
the quality of life. The beneficial effects of SSA in GEP 
NEN result from their multidirectional impact on the 
gastrointestinal system through inhibition of the secre-
tion of pancreatic and intestinal hormones, including 
insulin, glucagon, gastrin, secretin and VIP, as well as by 
inhibition of its motility and intestinal transportation, 
blood flow in the peritoneal vessels, and the growth 
and tissue differentiation [8, 18, 115].
Presently two SSA are available — octreotide and 
lanreotide, of which the most frequently used are 
preparations of prolonged action: octreotide-LAR im, 
and lanreotide Autogel sc. (every 4–8 weeks) [12, 116]. 
Therapy with long-acting SSA is the treatment of choice 
in cases of the following symptoms:
 — Carcinoid syndrome. Before the introduction of 
SSA, a large number of patients died as a result of 
complications due to carcinoid syndrome, including 
carcinoid crisis. Presently, during long-term treat-
ment with SSA, an improvement of clinical symp-
toms is observed, including diarrhoea and flushing, 
in 60–70% and 70–80% of patients with GEP NEN, 
respectively. Detailed dosing of SSA in the treat-
ment of carcinoid syndrome and carcinoid crisis is 
presented in the section on small intestinal NEN;
 — Glucagonoma. Improvement or disappearance of 
necrolytic migratory erythema was found in 80–90% 
of patients; lower efficiency is observed with respect 
to body weight loss control, diabetes and thrombo-
embolic disease;
 — VIPoma. Diarrhoea disappears and water-electrolyte 
disturbances improve in 80-90% of patients.
SSA are not the first-line therapy in insulinoma 
and gastrinoma [8]. In 50% of cases, insulin-producing 
tumours do not demonstrate SSTR2 or SSTR5 expres-
sion. Moreover, special care should be taken with in-
sulinoma patients, as SSA may increase hypoglycaemia 
(reduced glucagon secretion, reduced secretion of 
the growth hormone). However, in malignant forms 
of insulinoma, during SSA therapy clinical symptoms 
may be reduced, and the disease stabilised [117]. In the 
case of malignant forms of gastrinoma, using SSA as 
second-line therapy can also be effective in alleviating 
disease symptoms [99].
Short-acting SSA are still used if a prompt control of 
GEP NEN symptoms is required (including carcinoid 
crisis), in the peri-operative period or before introduc-
ing the treatment with long-acting analogues, in order 
to assess drug tolerance (e.g. in patients with insulinoma) 
[97, 99].
B. Stabilisation of the disease
SSA demonstrate an antiproliferative effect, which 
has been confirmed in in vitro and in vivo studies. The 
* evidence level according to CEBM [145]
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antineoplastic activity of SSA (cytotoxic and cytostatic) 
has been proven; it may consist in direct effect on the 
receptors on the tumour membrane cells, as well as in 
indirect impact by inhibiting the secretion of tumour 
growth factors, cytokines and hormones, which are 
responsible for uncontrollable growth and metastatic 
potential. Indirect effects also include inhibition of 
angiogenesis, induction of apoptosis and the impact 
on the immune system, particularly on the prolifera-
tion of lymphocytes and immunoglobulin synthesis 
[23]. A randomised, placebo-controlled, double-blind 
phase III study published in 2009 provided evidence 
on the antiproliferative effect of octreotide in patients 
with well-differentiated midgut NETs with metasta-
ses. Using octreotide LAR 30 mg extended the mean 
progression-free survival, and after six months of 
therapy the disease was stabilised in approximately 
67% of patients, regardless of NET’s hormonal activ-
ity. The progression-free survival was assessed as 
14.3 months, compared to six months in the control 
group [118]. The best result was achieved in patients 
with hepatic invasion of less than 10%, and resected 
primary tumour [119]. Some clinical trials have also 
demonstrated the antiproliferative effects of lan-
reotide: in the phase II study in patients with NEN 
(40% migut NEN, 27% pancreatic NEN) treated with 
lanreotide Autogel (120 mg every 28 days), the mean 
progression-free survival was 12.9 months.
Recently, the results of the randomised, double-
blind, placebo-controlled phase IIICLARINET study 
on the use of Lanreotide Autogel 120 mg in GEP NEN 
have been announced; they confirmed antiprolifera-
tive effect of this analogue [120]. The study involved 
204 patients with G1 and G2 nonfunctional NETs (Ki-67 
< 10%) with the primary location being in the pancreas 
(45%), midgut (36%), hindgut (7%) and unknown 
(13%), and with hepatic invasion > 25% in 33% of 
patients. Two-year treatment with Lanreotide Autogel 
120 mg every four weeks demonstrated the absence of 
disease progression or death in 62% of treated patients, 
compared to 22% of the placebo patients. Lanreotide 
Autogel statistically significantly extended the PFS vs. 
placebo (mean PFS was not achieved in the treatment 
group, compared to 18 months in the placebo group) 
(*evidence level 1).
A decision to introduce SSA to therapy should be 
taken individually for each patient. Previous study 
results have indicated that SSA therapy is beneficial 
in patients with functional and non-functional NENs 
(with a good somatostatin receptor expression) and/or 
slow progression of the disease, preferably in patients 
with low Ki-67 up to 10%. 
SSA are usually well-tolerated, and associated 
adverse reactions are rare. Initial side effects such 
as discomfort in the abdominal cavity, flatulence or 
steatorrhea usually disappear spontaneously within 
a few weeks, or during the symptomatic treatment (e.g. 
pancreatic enzymes preparations). Other side effects 
include impaired glucose tolerance and cholelithiasis, 
and occur in 20–50% of patients (rarely symptomatic) 
[18]. Therefore, if surgical treatment and long-term 
pharmacotherapy with long-acting SSA are planned, 
cholecystectomy should be considered. During a long-
term treatment with SSA, the response to treatment may 
be reduced or lost. This is explained by tachyphylaxis 
and resistance to treatment. It may be caused by re-
duced somatostatin receptor expression on the tumour 
cells due to down-regulation, loss of receptor sensitivity, 
heterogeneous receptor expression or growth of the 
clones of SSTR-negative cells [119].
Detailed information on treatment with SSA is pro-
vided in the section on small intestinal NENs. 
Currently, studies are being conducted on the use of 
new SSA, e.g. pasireotide (SOM-230), in the treatment 
of functional NENs, also those resistant to octreotide 
or lanreotide. 
The pre-operative pharmacological preparation of 
patients with the use of SSA has been discussed in the 
section on small intestinal NENs.
C. Interferon alpha
Interferon alpha (INF-a) is used for similar indications 
as SSA. As its effect in controlling clinical symptoms 
is delayed, it is not used in the treatment of carcinoid 
crisis. Due to a larger number of adverse reactions, it is 
the second-line treatment to control clinical symptoms 
of functional tumours. INF-a therapy may be indicated 
for GEP NENs with the proliferative index lower than 
2–3% [1, 121]. In Poland, there is no previous experience 
of using INF-a for GEP NEN management.
There are single reports concerning the use of 
interferon-alpha indicating that the patient may ben-
efit from this therapy only if the mitotic index of the 
tumour is low [122]. 
Minimal consensus statement on biotherapy:
Therapy with SSA is the treatment of choice in patients with 
functional and non-functional GEP NENs and/or slowly 
progressing disease, preferably in patients with low Ki-67 
proliferative index (*evidence level 1).
* evidence level according to CEBM [145]
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3.3.2. Chemotherapy and molecularly targeted 
therapy
Well-differentiated and moderately-differentiated 
neoplasms (G1 and G2)
The place of chemotherapy (using medicines 
with cytotoxic effect) in patients with GEP NENs 
depends primarily on the histological characteristics 
(differentiation grade of the neoplasm), and on its 
primary location. In patients with well-differentiated 
and moderately-differentiated neoplasms (G1 and 
G2), chemotherapy may be considered only in the 
advanced stage of the disease (incomplete primary 
surgical treatment results, or recurrence of the disease 
after initial radical treatment). The most important 
criterion in qualification for chemotherapy is symp-
tomatic character of the disease or its progression 
dynamics. Patients with the disease so advanced that 
it entails the risk of organ failure (e.g. liver, lungs), or 
causes clinical symptoms which cannot be controlled 
by other methods (e.g. pain), are qualified for the 
treatment. If these features are absent, the qualifica-
tion criterion may be confirmation of tumour progres-
sion according to RECIST criteria within the period 
of up to one year. RECIST progression in the period 
of more than a year is not treated as an independent 
indication for chemotherapy. 
In each case of advanced GEP NEN, before deciding 
on chemotherapy, palliative local treatment (excision, 
thermoablation or cryoablation of the metastases and 
embolisation), or less toxic methods of systemic man-
agement should be considered (biotherapy with cold 
SSA, isotope therapy with hot SSA — PRRT). The above 
suggestions are based on the opinions of experts, com-
pliant with most of the world’s management guidelines 
(*evidence level 5). 
The present state of knowledge does not justify 
using chemotherapy as an adjuvant therapy after com-
plete surgical management of G1-2 neoplasms (adju-
vant chemotherapy, with the intention to eradicate the 
foci of micro-diffusion). There is no conclusive evidence 
that it has a positive effect on extending the disease free 
survival (DFS) or overall survival (OS) of patients [123]. 
The effectiveness of chemotherapy on well-dif-
ferentiated or moderately-differentiated GEP NENs 
should be considered separately in cases of neoplasms 
of pancreatic origin, and those with different locations 
(stomach, duodenum, small intestine, appendix and 
large intestine). An indirect comparison of the results of 
clinical studies involving patients with GEP NENs dem-
onstrates a higher probability of response in patients 
treated due to pancreatic NENs (15–35% compared 
to 5–15%) [124]. Interpretation of the results of previ-
ous studies is difficult due to the heterogeneity of the 
groups of patients regarding prognostic factors, and the 
criteria used to assess the response (a considerable part 
of the studies involved patients who were not stratified 
according to the level of tumour differentiation; moreo-
ver, in earlier analyses, the radiological assessment of 
the response to chemotherapy was suboptimal from 
today’s perspective). 
In well-differentiated pancreatic NENs, the highest 
activity in monotherapy (response rate — 20–40%) is 
demonstrated by streptozocin, doxorubicin, fluoroura-
cil, dacarbazine and temozolomide. Using multi-drug 
regimens is more effective than monotherapy regarding 
the effect on response and survival rates (mean survival 
— 15–30 months). 
The use of streptozocin (STZ) in monotherapy re-
sulted in a response rate (RR) of approximately 36%, 
and OS of ca. 17 months. Combining streptozocin 
with 5-fluorouracil (5-FU) increased the response rate 
to 63%, and extended the mean overall survival to 
26 months [125]. A breakthrough in chemotherapy of 
pancreatic NENs was the phase III study by Moertel et 
al. in 1992 [126], in which 69 patients were randomised 
to two chemotherapy arms: streptozocin-based, i.e. 
with doxorubicin (DOX) and chemotherapy with 5-FU, 
demonstrating RR of 69% v. 45%, respectively, with 
mean clinical response time of 18 months vs. 14 months, 
and mean overall survival of 26 months v. 17 months 
(*evidence level 3). Although such positive outcomes 
could not be repeated in any subsequent clinical study, 
further publications confirmed the clinical response rate 
after the use of STZ + DOX or STZ + 5-FU of 35–55%, 
with the response time of 11–22 months, and the mean 
overall survival of a little over 20 months [124, 127] 
(*evidence level 4). 
More recent studies, conducted in the 21st century, 
have documented the effectiveness of chemotherapy 
with streptozocin combined with doxorubicin. Delau-
noit et al. [128] demonstrated RR = 36% and a two-year 
and three-year OS in 50% and 24% of 45 patients with 
pancreatic G1/G2 NENs, respectively. 
Kouvaraki [129], adding 5-FU to streptozotocin and 
doxorubicin (FAS regimen), in a group of 63 patients 
achieved RR = 39%, with a response time of 9.3 months, 
as well as a two-year PFS in 41% and a two-year OS 
in 71% of patients. The study by Kouvaraki et al. sug-
gests that there is no statistically significant correlation 
between OS and the tumour type, histological differen-
tiation or surgical resection; however, progression-free 
survival was characteristically shorter in poorly dif-
* evidence level according to CEBM [145]
436
Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms  Beata Kos-Kudła et al.
ferentiated NENs (p = 0.003), and when FAS chemo-
therapy was used as the second-line treatment (p = 
0.05). In statistical multifactorial analysis, only the size 
of metastases in the liver (> 75% invasion of the organ) 
was associated with shorter PFS [130]. Substituting STZ 
with dacarbazine (e.g. the FDE regimen — 5-fluoroura-
cil + dacarbazine + epirubicin) was associated with 
lower RR (11%) and shorter response time (mean ten 
months) [124,128] (*evidence level 4).
It is worth noting that comparison of the results of 
the studies has not provided conclusive evidence that 
an increased number of medications in the regimen 
improves the treatment outcome, although it may be 
associated with a greater risk of adverse reactions. How-
ever, studies conducted over a long period of time (i.e. 
more than 20 years) do not allow a direct comparison 
of the response rates and progression-free survival, as 
the groups of patients and methods of monitoring the 
therapy are significantly different. 
Considering the above, in palliative chemotherapy 
of pancreatic NENs, the expert panel recommends 
combining streptozocin (the medicine is not registered 
in Poland, but is available as a direct import) with 
doxorubicin and fluorouracil, and in patients with 
a greater risk of complications or not qualifying for the 
treatment including anthracyclines, using a two-drug 
chemotherapy. 
It is difficult to assess the actual value of chemo-
therapy in patients with well-differentiated and 
moderately-differentiated GEP NENs located outside 
the pancreas, due to a limited number of studies and 
their contradictory results. Chemotherapy regimens 
are analogous to those used for pancreatic neoplasms, 
although there is no evidence of effectiveness of the 
streptozocin-based therapy. In clinical practice, a regi-
men with doxorubicin and 5-fluorouracil is usually 
chosen (*evidence level 5).
The value of proliferation index is unquestionably 
a prognostic factor (Ki-67 > 10% — worse prognosis). 
The predictive value of increased proliferation index 
— considered as an additional factor while deciding on 
the chemotherapy treatment — requires confirmation 
in prospective studies (retrospective analyses of previ-
ous studies suggest a higher probability of response in 
patients with increased Ki-67 value) [130].
In patients with pancreatic NEN (PNEN), it is now 
possible to use new, molecularly targeted medicines, 
including primarily two available medicines, everoli-
mus and sunitinib, which are treatment options in 
advanced disease. They are discussed in the section on 
recommendations for PNENs (pp. 459–479).
Poorly-differentiated neoplasms (G3) — neuroendo-
crine carcinomas
Chemotherapy is the basic method of palliative 
treatment in advanced, poorly-differentiated NENs 
(G3). A standard procedure in the case of disease 
progression following the surgical treatment of 
poorly-differentiated GEP NENs, incomplete surgical 
procedure or metastases, is chemotherapy with cispl-
atin and etoposide-based regimens, which results in 
an objective response in 40–70% of patients (includ-
ing complete response in approximately 20–25% of 
patients), with mean survival of 12–15 months [131] 
(*evidence level 3).
This regimen, modified by introduction of a third 
medicine (paclitaxel) and the substitution of cisplatin 
with carboplatin, results in response and survival exten-
sion in a large group of patients, but at the same time 
significantly increases the risk of myelotoxicity [126]. 
In clinical practice, it is not recommended to use other 
regimens (e.g. cisplatin and irinotecan, or oxaliplatin 
and fluorouracil with calcium folinate) as the first-line 
treatment. Implementation of the second-line chemo-
therapy (after progression following therapy with cis-
platin and etoposide) may be individually considered 
only in patients with good function; in the case of 
a long-term response to the first-line therapy, it may be 
considered to repeat this therapy; in resistant patients 
another chemotherapy regimen can be introduced 
(*evidence level 4) for the use of irinotecan, 5-fluorouracil 
and sodium folinate [132].
In neuroendocrine carcinoma (NEC), introduction 
of adjuvant therapy may be considered in patients 
undergoing radical surgical treatment. In patients with 
small cell G3 neoplasms, adjuvant chemotherapy based 
on platinum analogues should be standard procedure 
— it seems, although there are no randomised studies, 
that in this group of patients, by analogy to small cell 
lung carcinoma, chemotherapy including cisplatin (or 
carboplatin) with etoposide may prolong disease-free 
survival (*evidence level 4). In some cases, certain groups 
of experts recommend also using adjuvant radiothera-
py, although here there is no conclusive evidence either 
for the benefits of such treatment — this therapy may be 
considered in patients after radical resections of locally 
advanced NECs, e.g. of the stomach or rectum, but the 
decision must be highly individualised. 
Similarly, a highly individualised therapeutic 
decision must be made in the case of indications for 
adjuvant chemotherapy in patients with large cell 
neuroendocrine carcinoma — this applies to a large 
proportion of all neuroendocrine tumours.
* evidence level according to CEBM [145]
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Minimal consensus statement on chemotherapy and 
targeted therapy:
 — Advanced G1/G2 NENs — systemic chemotherapy 
including streptozocin with doxorubicin (± 5-FU) 
(*evidence level 3).
 — If the disease progresses after chemotherapy, everolimus 
or sunitinib (± SSA) in pancreatic NENs (*evidence 
level 1).
 — The basic treatment of NEC is chemotherapy based on 
the cisplatin plus etoposide regimen (*evidence level 3).
3.4. Radioisotope treatment
3.4.1. Peptide Receptor Radionuclide Therapy (PRRT)
Patients with advanced, non-surgical GEP NENs are 
qualified for isotope treatment. There are no indications 
for isotope treatment as an adjuvant therapy following 
radical surgical management.
Isotope-labelled SSA and metaiodobenzylguanidine 
are used in the isotope therapy of NENs.
A. Treatment with isotope-labelled SSA
Previous experience in isotope therapy of GEP NENs 
comprises mostly the use of DOTA-Tyr3-octreotide 
and DOTA-Tyr3-octreotate labelled with the isotopes 
177Lu, 90Y, or a combination of the two. Data from non-
randomised clinical studies indicates that a response 
to treatment (complete or partial remission) can be 
achieved in approximately 8–46% of patients, and the 
mean progression-free survival after the treatment 
is 25 to 36 months [133–141]. These studies apply 
mostly to patients with well-differentiated neoplasms 
(G1 and G2), and these recommendations are for this 
group of patients. Presently, no results of prospective, 
randomised clinical studies are available to assess the 
effectiveness of the therapy with isotope-labelled SSA (a 
study comparing the effectiveness of 177Lu + octreotide 
v. octreotide is in progress).
Patients with intensive collection of tracer in all the ne-
oplastic foci, in the case of small lesions with homogenous 
tracer collection, are good candidates for the treatment. 
If not all of the neoplastic foci collect radiopeptide and/or 
large foci of necrosis are found, the aim of the treatment 
is a palliative effect in the form of extended progression-
free survival, and reduction of the neoplastic disease 
symptoms (e.g. pain, carcinoid syndrome symptoms). In 
individual cases, isotope therapy as a neoadjuvant treat-
ment may be considered in order to reduce the tumour 
mass before the surgical treatment [142].
Qualification for the treatment with isotope-labelled SSA
Qualified for the treatment with isotope-labelled 
SSA are patients with well-differentiated NENs, which 
demonstrate high somatostatin receptor expression 
confirmed by receptor scintigraphy SPECT or PET/CT 
examination — collection should be at least comparable 
with a collection of radiotracer in the healthy liver, or 
higher [137].
Exclusion criteria for PRRT treatment
1. Patients younger than 18 years.
2. Pregnant patients (a negative pregnancy test 
is required).
3. Assessment of the patient’s performance status 
(PS) according to the WHO classification PS 
status 3 or 4, or according to Karnofsky clas-
sification (< 60).
4. Abnormal blood test results:
 — Hb < 8g/dL,
 — platelets < 80x103/μL,
 — WBC < 2x103/μL*,
 — Lymphocytes < 0.5x103/μL,
 — Neutrocytes below 1x103/μL,
 — Renal failure (GFR < 30 mL/min)*, BUN > 
45 mg/dL; creatinine > 150 μmol/L
 — Liver failure (bilirubin > 30 μL/min.)*.
Due to increased risk of adverse reactions, patients 
with leukocytosis < 3,000, neutropoenia < 1,500, throm-
bocytopoenia < 100,000 and creatinine clearance < 60 
mg/mL, should be qualified for the treatment individu-
ally [137, 139].
Qualification tests before starting the PRRT:
Neuroendocrine tumour confirmed by histopatho-
logical examination or biopsy:
 — Positive result of receptor scintigraphy with labelled 
somatostatin receptors within 12 weeks from start-
ing the therapy, in order to assess the radioisotope 
collection in the lesions;
 — Before the therapy, or within three weeks of it 
starting, the patient should undergo a multiphase 
CT examination, or, alternatively, a dynamic MR 
examination to assess the extent of the disease;
 — GFR assessment (in non-conclusive cases, assess-
ment based on a scintigraphic examination is rec-
ommended);
 — Before the treatment, the patient should have the 
following laboratory tests:
• Complete blood count with a smear,
• Urea and creatinine, uric acid, with biochemical 
assessment of GFR,
• ALAT, ASPAT,
• CgA,
• Other laboratory tests according to the clinical 
stage,
* evidence level according to CEBM [145]
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• Patient’s informed consent for the treatment 
is required.
Depending on the dosimetric data, the therapy may 
be conducted in out-patient settings; in special cases, 
determined by the clinical condition, it may take place 
in hospital [139].
Isotope treatment regimens
Treatment is usually conducted in 4-5 cycles, with 
intervals of 6–12 weeks, with the use of SSA labelled 
with 90Y 177Lu, or 90Y/177Lu. During isotope treatment, it 
is necessary to administer intravenously a solution of 
amino acids for radioprotection of the kidneys [137, 139].
There is no conclusive evidence that treatment 
with octreotide/lanreotide reduces the effectiveness of 
isotope-labelled SSA therapy. This therapy should not 
be discontinued during isotope treatment; however, it 
would be best if the interval between administrations 
of a long-acting analogue was 4–7 weeks. If the treat-
ment with a SSA needs to be continued, short-acting 
analogues are recommended [140].
Side-effects of the treatment with isotope-labelled SSA
The side effects of the treatment mostly affect the 
haematopoietic system and kidneys. Possible adverse 
reactions should be monitored. The risk of post-radiation 
damage to the kidneys is reduced by intravenous admin-
istration of positively charged amino acids — L-lysine + 
+ arginine — prior to the treatment. Patients with car-
cinoid syndrome, who may experience carcinoid crisis 
during therapy, require special attention. Short-acting 
SSA should be used with these patients [141,142]. 
Retreatment with isotope-labelled SSA
In the case of progression after achieving a long-
lasting, good effect of isotope therapy, retreatment may 
be considered [141].
Depending on dosimetric data, the therapy may 
be conducted in out-patient settings; in special cases 
determined by the patient’s clinical condition, it may 
take place in hospital conditions.
3.4.2. Treatment with 131I-mIBG 
Treatment with 131I-mIBG may be considered in patients 
with negative receptor scintigraphy results, and m-IBG 
collection in the tumour and/or in the metastases. This 
treatment is primarily palliative, and enables reduction 
of pain and carcinoid syndrome symptoms. A treatment 
with radical intention is rarely possible [143, 144]. Con-
traindications for the therapy include bone marrow sup-
pression (according to the above criteria). In patients with 
a functional thyroid gland, it is necessary to block the 
uptake of free iodine 131 not bound with mIBG carrier 
(Lugol’s solution or sodium perchlorate may be used).
Qualification for isotope treatment
Basic tests performed to qualify a patient for isotope 
treatment include diagnostic 131I-mIBG scintigraphy, and 
comparing the location of tracer collection with locations 
of metastatic foci in a CT or MR examination, complete 
blood count with a smear, and liver and kidney function 
tests, including creatinine clearance [141, 142]. 
3.4.3. Evaluation of therapy effects
Evaluation of therapy effects should include morpho-
logical examinations (e.g. CT, MR) and functional tests 
(scintigraphy/receptor PET) three months after the 
treatment, then every six months for two years. Further 
supervision depends on the clinical course of the dis-
ease. The optimal criteria for evaluation of the therapy 
effects are still under discussion [140]. 
3.4.4. Place of isotope treatment in the therapy  
of advanced neuroendocrine neoplasms
The literature does not offer conclusive data on the 
GEP NEN treatment stage at which isotope treatment 
should be considered. Progression of the neoplastic 
disease is an indication for the implementation of 
cytotoxic therapy (chemotherapy/radiotherapy/tar-
geted therapy), but there are no studies evaluating 
which of these is the most effective as the first-line 
treatment. 
It seems that location of the primary focus and high 
expression of somatostatin receptors should be taken into 
account. In patients with a high somatostatin receptor 
expression, depending on the stage of the disease, PPRT 
may be considered as the first-line treatment [138, 140]. 
3.5. Summary
Treatment of patients with non-surgical GEP NENs 
should be conducted using isotope-labelled (177Lu and 
90Y) SSA (*evidence level 3).
Treatment of patients with non-surgical GEP NENs 
with negative receptor scintigraphy results should be 
conducted using 131I-mIBG (*evidence level 3).
Minimal consensus statement on radioisotope treatment:
PPRT may be considered as the first-line treatment in pa-
tients with high somatostatin receptor expression, depending 
on the stage of the disease (*evidence level 4).
* evidence level according to CEBM [145]
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4. Follow-up
Monitoring of the treatment should include clinical ex-
aminations, laboratory tests (CgA) and imaging methods.
It is recommended to monitor the disease by means 
of imaging examinations, such as USG, MR and CT, 
endoscopic examinations, and determination of bio-
chemical markers (CgA) every 6–12 months in G1-G2 
NETs. Functional imaging (SRS or 68Ga PET/TC) should 
be performed 4–6 months after the surgical treatment. 
In NETs demonstrating somatostatin receptor expres-
sion, it should be repeated every 12–24 months and 
in further follow-up depends on the tumour clinical 
advancement and location. 
In patients with NEC, imaging examinations should 
be performed every 3–6 months, depending on the 
course of the disease. 
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